.

Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
Julphar
Teva
Baxter
AstraZeneca
US Army
UBS
Johnson and Johnson
Cerilliant

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,369,085

« Back to Dashboard

Which drugs does patent 6,369,085 protect, and when does it expire?


Patent 6,369,085 protects NEXIUM, NEXIUM 24HR, and VIMOVO, and is included in six NDAs. There have been zero Paragraph IV challenges on Vimovo and Nexium

Protection for NEXIUM has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has seventy-three patent family members in forty-two countries.

Summary for Patent: 6,369,085

Title: Form of S-omeprazole
Abstract:The present invention relates to a novel form of the (-)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-ben zimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.
Inventor(s): Cotton; Hanna (Sodertalje, SE), Kronstrom; Anders (Sodertalje, SE), Mattson; Anders (Sodertalje, SE), Moller; Eva (Sodertalje, SE)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:09/077,719
Patent Claim Types:
see list of patent claims
Compound; Use; Process; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca PharmsNEXIUMesomeprazole magnesiumCAPSULE, DELAYED REL PELLETS;ORAL021153-001Feb 20, 2001ABRXYesNo► Subscribe► SubscribeY► Subscribe
Astrazeneca PharmsNEXIUMesomeprazole magnesiumCAPSULE, DELAYED REL PELLETS;ORAL021153-002Feb 20, 2001ABRXYesYes► Subscribe► SubscribeY► Subscribe
Astrazeneca LpNEXIUM 24HResomeprazole magnesiumCAPSULE, DELAYED RELEASE;ORAL204655-001Mar 28, 2014OTCYesYes► Subscribe► SubscribeY► Subscribe
Astrazeneca PharmsNEXIUMesomeprazole magnesiumFOR SUSPENSION, DELAYED RELEASE;ORAL021957-003Dec 15, 2011RXYesNo► Subscribe► SubscribeY► Subscribe
Astrazeneca PharmsNEXIUMesomeprazole magnesiumFOR SUSPENSION, DELAYED RELEASE;ORAL021957-004Dec 15, 2011RXYesNo► Subscribe► SubscribeY► Subscribe
Astrazeneca PharmsNEXIUMesomeprazole magnesiumFOR SUSPENSION, DELAYED RELEASE;ORAL022101-001Feb 27, 2008RXYesNo► Subscribe► SubscribeY► Subscribe
Astrazeneca PharmsNEXIUMesomeprazole magnesiumFOR SUSPENSION, DELAYED RELEASE;ORAL021957-001Oct 20, 2006RXYesNo► Subscribe► SubscribeY► Subscribe
Astrazeneca PharmsNEXIUMesomeprazole magnesiumFOR SUSPENSION, DELAYED RELEASE;ORAL021957-002Oct 20, 2006RXYesYes► Subscribe► SubscribeY► Subscribe
Astrazeneca LpNEXIUM 24HResomeprazole magnesiumTABLET, DELAYED RELEASE;ORAL207920-001Nov 23, 2015OTCYesYes► Subscribe► SubscribeY► Subscribe
Horizon Pharma UsaVIMOVOesomeprazole magnesium; naproxenTABLET, DELAYED RELEASE;ORAL022511-002Apr 30, 2010ABRXYesNo► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,369,085

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9702065May 30, 1997
PCT Information
PCT FiledMay 05, 1998PCT Application Number:PCT/SE98/00974
PCT Publication Date:December 03, 1998PCT Publication Number: WO98/54171

Non-Orange Book Patents for Patent: 6,369,085

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,677,455 Potassium salt of S-omeprazole► Subscribe
8,466,175Form of S-omeprazole► Subscribe
7,745,466Form of S-omeprazole► Subscribe
8,076,361Form of S-omeprazole► Subscribe
7,411,070Form of S-omeprazole► Subscribe
6,747,155 Process► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,369,085

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan538040► Subscribe
Turkey9902934► Subscribe
TunisiaSN98074► Subscribe
Slovakia285137► Subscribe
Slovakia284837► Subscribe
Slovakia162599► Subscribe
Slovenia1273581► Subscribe
Slovenia0984957► Subscribe
Sweden510650► Subscribe
Sweden9702065► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Chinese Patent Office
Chubb
Novartis
Accenture
McKinsey
Julphar
Merck
AstraZeneca
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot